Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| 27.88 | |
| 28.22 | |
| - | |
| 28.95 | |
| 27.66 | |
| 22.01-32.88 | |
| 4 617 M | |
| 12.2982 | |
| 165 M | |
| 1 508 M | |
| 0.7 | |
| 0.437 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Alkermes plc ALKS reported adjusted earnings from continuing operations of 72 cents per share for second-quarter 2024, which missed the Zacks Consensus Estimate of 73 cents. The company had reported a...
For the quarter ended June 2024, Alkermes (ALKS) reported revenue of $399.13 million, down 35.4% over the same period last year. EPS came in at $0.72, compared to $0.55 in the year-ago quarter. The r...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
